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WS17.1 Bioﬁlm disruption and potentiating antimicrobial effects of
a novel alginate oligomer on Pseudomonas aeruginosa in a
murine lung infection model
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1Rigshospitalet, University Hospital of Copenhagen, Department of Clinical
Microbiology, Copenhagen, Denmark; 2University of Copenhagen, Institute for
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3AlgiPharma AS, Sandvika, Norway
P. aeruginosa growing as a bioﬁlm is the main cause of chronic lung infection
in cystic ﬁbrosis (CF) patients. A novel alginate oligomer (OligoG CF-5/20) has
been shown to disrupt bioﬁlm and potentiate activity of selected antibiotics. Recent
studies have demonstrated a synergistic effect of OligoG with colistin in disrupting
bioﬁlms of P. aeruginosa NH57388A in vitro. The aim of this study was to
determine in vivo effect of OligoG in a murine bioﬁlm lung infection model.
OligoG CF-5/20 is a linear sodium alginate oligomer with an average degree of
polymerisation Dp 13 comprising predominantly a-L-guluronate (AlgiPharma AS,
Norway). A clinical isolate of P. aeruginosa NH57388A obtained from the lung
of a CF patient was used in this model. A bioﬁlm was simulated using NH57388
(1×108cfu/ml) embedded in alginate beads using Pronova LVG (FMC Biopoly-
mer/NovaMatrix, Norway). Balb/cj mice (8 mice/group) were lightly anaesthetized
and 0.04mL of the bead embedded NH57388A administered by intra-tracheal route
to the lower left lung of mouse, with or without 5% OligoG (50mg/mL). A single
dose of colistin was administrated intraperitoneally 2hr after bacterial challenge.
The concentrations of colistin used were 0.4mg/kg, 1.6mg/kg and 6.4mg/kg. Lungs
were removed at sacriﬁce 24hr after bacterial challenge to determine bacterial counts
and macropathology. Results with colistin-OligoG combinations were signiﬁcantly
better than colistin alone with almost three log reduction in lung bacterial burden.
Furthermore, a two log reductions in lung bacterial burden was also observed in
this model when 5% OligoG was administered alone. Phase IIa clinical trials with
OligoG are in progress.
WS17.2 ALX-109 potentiates the effect of inhaled antibiotics at killing
Pseudomonas aeruginosa bioﬁlms on human airway cells
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Objectives: Iron has been shown to promote P. aeruginosa bioﬁlm formation on
airway cells and the iron concentration in the airway surface liquid of CF lung
is 400-times higher than in a non-CF lung. Chelating iron may be a promising
new therapy to eliminate bioﬁlms on CF airway cells. Here, we investigate whether
P. aeruginosa bioﬁlms would become more susceptible to the action of inhaled
tobramycin (Tb) and inhaled aztreonam in the presence of ALX-109, a new
investigational drug containing lactoferrin − an iron-binding glycoprotein − and
hypothiocyanite.
Methods: Bioﬁlms were grown at the apical surface of polarized human CF airway
epithelial cells, using a co-culture model we previously described.
Conclusion: ALX-109 and Tb (5mg/ml) together decreased established PAO1
bioﬁlms by 7 log units, an effect signiﬁcantly larger than Tb alone (p< 0.05). The
efﬁcacy of ALX-109 and Tb together was also tested on bioﬁlms formed by clinical
P. aeruginosa strains isolated from the sputum of CF patients. The combination of
Tb and ALX-109 was additive for mucoid clinical isolates, reducing bioﬁlms by
2.5 to 3 log units, compared with ~1 log unit for each compound alone (p< 0.05).
At all doses of Tb tested (5–500 ug/ml), ALX-109 signiﬁcantly disrupted bioﬁlms
compared with Tb alone. Similarly, the combination of ALX-109 and aztreonam
reduced bioﬁlm formation on airway cells by 4 log units, compared with 0 and 3
log units, respectively, for each compound alone.
Inhalation therapy combining tobramycin or aztreonam with ALX-109 may be
beneﬁcial to CF patients infected with P. aeruginosa. Phase I clinical trials are
planned.
WS17.3 Allicin revisited: Antimicrobial activity against the
Burkholderia cepacia complex and interaction with a
peroxidase target
C. Doherty1, D. Wallock2, L. Doherty1, D. Clarke2, J. Govan1, D. Campopiano2.
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The antimicrobial activity of garlic and other alliums is primarily attributed to
allicin [1], an alliin-derived unstable thiosulphinate (allyl 2-propenethiosulﬁnate)
present in crushed garlic bulbs but usually lost in medicinal formulations. In re-
sponse to the challenges of treating Burkholderia cepacia complex (Bcc) infections
with existing antimicrobials [2], we sought to identify allicin in aqueous garlic
extracts (AGE) and investigate bactericidal activity against a Bcc panel. We used
hplc and electrospray ionisation mass spectrometry (LC ESI-MS) to characterise a
pure allicin standard and calculate the allicin content of fresh garlic extracts [3,4].
We report the ﬁrst evidence for the bactericidal activity of both puriﬁed allicin and
AGE against the Bcc. MICs of AGE for 38 Bcc strains ranged from 0.5 to 3%,
MIC90 1%. In agar diffusion assays, AGE was more active against B. cenocepacia
J2315 than the existing agents ceftazidime, ciproﬂoxacin and meropenem. The
mechanisms involved in the bactericidal action of allicin are poorly understood.
Studies on the interaction of allicin and an enzyme target (recombinant BCP
peroxiredoxin (Bc BCP Prx) from Burkholderia cenocepacia J2315) [5] using
Fourier transform ion cyclotron resonance MS (FT-ICR MS) suggest that allicin
reacts with the peroxidatic Cys44 residue of the Bc BCP Prx to produce a new
mixed disulﬁde derivative.
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WS17.4 Anti-pseudomonal bacteriophage cocktail reduces inﬂammatory
responses in the murine lung
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We hypothesised that bacteriophage cocktails (BPC) may be useful against Pseudo-
monas aeruginosa (Pa) in cystic ﬁbrosis (CF) & tested this in a murine model.
Methods: Two Pa strains were tested:
a. a non-mucoid, clinical CF strain,
b. Pa01.
Both were sensitive to BPC in vitro on standard plaque assays.
Adult BALB/c mice were inoculated intranasally with Pa and BPC (treated, n = 21)
or buffer (control, n = 21). 12 mice were sacriﬁced 24hrs post-infection and the others
at 48hrs. Bronchoalveolar lavage (BAL) was serially diluted for quantitative culture;
spleen homogenate was cultured in a non-quantitative fashion. Total and differential
cell counts were performed on BAL and inﬂammatory markers were measured.
Results: All treated mice cleared infection at 24 hrs (n = 6) compared with none of
the controls (n = 6) in whom there was a median [range] CFU/ml 1305 [190–4700],
p< 0.01); inﬂammatory cell counts at this time point did not differ. At the 48hr time
point all mice had cleared infection but there were signiﬁcantly fewer neutrophils
in BAL of treated mice compared with controls (median [range] 174 [112.1–266.8]
×104/ml vs. 73.2 [35.2–102.1], p< 0.01 for the clinical strain; median [range] 206
[160.1–331.6] x104/ml vs. 122.1 [105.4–187.4], p< 0.01 for Pa01). Cytokines including
IL-12p70, IL-6, TNF-a and IL-10 were signiﬁcantly lower in treated mice than controls.
Conclusions: BPC co-administration led to
a. more rapid clearance of Pa and
b. a reduced inﬂammatory response in this acute murine model.
Further work is underway to explore the therapeutic potential of bacteriophage in
pulmonary Pa infection; preliminary data where BPC is administered 24hrs after initial
infection shows promise.
